Enzymatica approved for listing on Nasdaq First North – trading to start June 15, 2015
Enzymatica AB has been approved for trading on Nasdaq First North Stockholm. The last day of trading on AktieTorget is Friday, June 12 and the first day of trading on Nasdaq First North is Monday June 15, 2015. In connection with the listing the Board of Enzymatica has drawn up a company description that has now been published in Swedish.
As part of Enzymatica’s development and increased international presence, the Board of Enzymatica has applied for, and has received, approval for admission to trading of its shares on Nasdaq First North. The listing on First North is a natural step towards Nasdaq's main list.
The company's shareholders need not take any action in connection with the listing. The shares will continue to trade under the ticker ENZY with ISIN code SE0003943620. Erik Penser Bankaktiebolag will act as Certified Adviser for Enzymatica.
For further information please refer to the company description drawn up for the listing on Nasdaq First North. The document is available on the company's Swedish website www.enzymatica.se/IR.
Company Presentation in Stockholm on June 11 at 12-13
On June 11 at 12-13 CEO Fredrik Lindberg will present the company at Remium, Kungsgatan 12-14 in Stockholm. Seats are limited and Remium requests interested parties to register their interest as soon as possible via email event@remium.com. For questions, please contact Remium on +46 8-454 32 00 or via email event@remium.com.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 708-86 53 70 | E-mail: fredrik.lindberg@enzymatica.com
Lennart Nilsson, Chairman of the Board, Enzymatica AB
Tel: +46 46-286 31 00. E-mail: ir@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme® and launched it on four markets. The product became the leading article for colds in Swedish pharmacies during winter 2014-2015. Development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The company is headquartered in Lund, Sweden and has been listed on AktieTorget since 2011. For more information, please visit www.enzymatica.com.
Tags: